Sequential

Executive Summary

Sequential is a UK-based biotech that combines artificial intelligence with gene therapy to develop treatments for rare genetic diseases. Founded in 2020, the company’s proprietary AI platform analyzes genomic data to identify optimal therapeutic targets and design precise gene therapy vectors, aiming to accelerate personalized medicine for underserved patient populations. By integrating computational biology with established gene therapy techniques, Sequential seeks to overcome traditional bottlenecks in target discovery and vector engineering, potentially reducing development timelines for rare disease therapies. Currently operating at the preclinical stage, Sequential has not yet disclosed specific pipeline candidates or raised public funding. The company faces the typical challenges of early-stage biotech, including proving platform validity in vivo and securing capital to advance toward the clinic. However, its AI-driven approach differentiates it in the competitive rare disease space, and a successful lead candidate selection or strategic partnership could significantly enhance its valuation. With a lean team and focus on scalable technology, Sequential is positioned to attract interest from investors and collaborators seeking innovative gene therapy solutions.

Upcoming Catalysts (preview)

• Q4 2026Lead Candidate Nomination for a Rare Disease Program70% success
• Q2 2026Strategic Partnership or Licensing Deal with a Gene Therapy Developer50% success
• Q3 2026Series A Financing Round60% success